Heterozygosity for ABCA1 gene mutations: Effects on enzymes, apolipoproteins and lipoprotein particle size

Atherosclerosis

Volumn 171, Issue 2, 2003, Pages 311-319

  Kuivenhoven, J A ^a   Hovingh, G K ^a   Van Tol, A ^b   Jauhiainen, M ^c   Ehnholm, C ^c   Fruchart, J C ^d   Brinton, E A ^e   Otvos, J D ^f   Smelt, A H M ^g   Brownlee, A ^h   Zwinderman, A H ⁱ   Hayden, M R ^j   Kastelein, J J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d INSERM   (France)

^e CARL T HAYDEN VA MEDICAL CENTER   (United States)

^f NORTH CAROLINA STATE UNIVERSITY   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Xenon Genetics Inc   (Canada)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

ABCA1; CETP; HDL; LCAT; PLTP

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; ENZYME; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LIPOPROTEIN A1; LIPOPROTEIN A2; LIPOPROTEIN C3; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILY; FEMALE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; LIPID ANALYSIS; LIPOPROTEIN METABOLISM; MALE; MEASUREMENT; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHOOL CHILD; SEX DIFFERENCE; SIBLING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0344033709     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.08.014     Document Type: Article

References (39)

1. Marcil M., Brooks-Wilson A., Clee S.M., et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 354:1999;1341-1346.
2. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:1999;352-355.
3. Fredrickson D.S., Altrocchi P.H., Avioli L.V., Goodman D.S., Goodman H.C. Tangier Disease. Ann. Int. Med. 55:1961;1016-1031.
4. Schaefer E.J., Zech L.A., Schwartz D.E., Brewer H.B. Jr. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann. Int. Med. 93:1980;261-266.
5. Serfaty-Lacrosniere C., Civeira F., Lanzberg A., et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 107:1994;85-98.
6. Asztalos B.F., Brousseau M.E., McNamara J.R., Horvath K.V., Roheim P.S., Schaefer E.J. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis. 156:2001;217-225.
7. Clee S.M., Kastelein J.J., van Dam M., et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J. Clin. Invest. 106:2000;1263-1270.
8. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans affairs high-density lipoprotein intervention trial. Am. J. Cardiol. 86:2000;19L-22L.
9. Pritchard PH, Hill JS. Genetic disorders of lecithin: cholesterol acyltransferase. In: Betteridge DJ, Illingworth DR, Shibuya YA, editors. Lipoproteins in health and disease; 1999. p. 799-814.
10. Attie A.D., Kastelein J.P., Hayden M.R. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J. Lipid Res. 42:2001;1717-1726.
11. Srivastava N. ATP binding cassette transporter A1-key roles in cellular lipid transport and atherosclerosis. Mol. Cell Biochem. 237:2002;155-164.
12. Otvos J.D., Jeyarajay E.J., Bennett D.W., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin. Chem. 38:1992;1632-1638.
13. Brousseau M.E., Eberhart G.P., Dupuis J., et al. Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J. Lipid Res. 41:2000;1125-1135.
14. van Dam M.J., de Groot E., Clee S.M. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 359:2002;37-42.
15. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:1999;336-345.
16. Warnick G.R., Nguyen T., Albers A.A. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin. Chem. 31:1985;217-222.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
18. Schwarz S., Hass B., Luley C., Schafer J.R., Steinmetz A. Quantification of apolipoprotein in human plasma by immunonephelometry. Clin. Chem. 40:1994;1717-1721.
19. Bury J., De Keersgieter W., Rosseneu M., Belpaire F., Christophe J. Immunonephelometric quantitation of the apolipoprotein CIII in human plasma. Clin. Chim. Acta. 145:1985;249-258.
20. Weisweiler P., Schwandt P. Immunonephelometric quantitation of apolipoprotein E in human serum. J. Clin. Chem. Clin. Biochem. 21:1983;227-230.
21. Speijer H., Groener J.E., van Ramshorst E., van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis. 90:1991;159-168.
22. Joles J.A., Willekes-Koolschijn N., Scheek L.M., Koomans H.A., Rabelink T.J., van Tol A. Lipoprotein phospholipid composition and LCAT activity in nephrotic and analbuminemic rats. Kidney Int. 46:1994;97-104.
23. Luc G., Bard J.M., Ferrieres J., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler. Thromb. Vasc. Biol. 22:2002;1155-1161.
24. Grundy S.M., Vega G.L., Otvos J.D., Rainwater D.L., Cohen J.C. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacologic evidence. J. Lipid Res. 40:1999;229-234.
25. Clee S.M., Zwinderman A.H., Engert J.C., et al. Common genetic variation in ABCAI is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation. 103:2001;1198-1205.
26. Duchateau P., Rader D., Duverger N., et al. Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I:A-II and LpA-IV particles from plasma. Biochim. Biophys. Acta. 1182:1993;30-36.
27. Russo G.T., Meigs J.B., Cupples L.A., et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis. 158:2001;173-181.
28. von Eckardstein A., Huang Y., Wu S., et al. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler. Thromb. Vasc. Biol. 15:1995;1755-1763.
29. Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 1997;99:1906-16.
30. Remaley A.T., Stonik J.A., Demosky S.J., et al. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem. Biophys. Res. Commun. 280:2001;818-823.
31. Jiang X.C., Qin S., Qiao C., et al. Apolipoprotein B secretion and atherosclerosis are decreases in mice with phospholipid-transfer protein deficiency. Nat Med. 7:2001;847-852.
32. Lie J., de Crom R., van Gent T., et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J. Lipid Res. 43:2002;1875-1880.
33. van Haperen R., van Tol A., van Gent T., et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J. Biol. Chem. 277:2002;48938-48943.
34. van Tol A. Phospholipid transfer protein. Curr. Opin. Lipidol. 13:2002;135-139.
35. Karkkainen M., Oka T., Olkkonen V.M., et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J. Biol. Chem. 277:2002;15413-15418.
36. Shinkai H. New approaches to raising the HDL cholesterol level. Mini. Rev. Med. Chem. 2:2002;271-276.
37. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2002;2159-2165.
38. Wellington C.L., Yang Y.Z., Zhou S., et al. Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. J. Lipid Res. 43:2002;1939-1949.
39. Blake G.J., Otvos J.D., Rifai N., Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 106:2002;1930-1937.